Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Eli Lilly is one of the top growing stocks at the moment. Learn the reasons why this might be a stock to consider.

People with obesity who took Eli Lilly's daily oral GLP-1 drug orforglipron lost an average of 12.4% of their body weight, ...

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

Eli Lilly raised the price of its GLP-1, Zepbound, from about $125 to $165 and plans an additional hike next month that would ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...

Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill ...

Eli Lilly reported its GLP-1 pill helped patients lose 12.4% body weight in trials, less than Novo Nordisk's Wegovy. Lilly shares dropped 15%, wiping $100 billion from its market value. However, ...

As Eli Lilly and Novo Nordisk have been battling it out to gain market share of the growing GLP-1 weight loss market, one ...

GLP-1 drugs for diabetes and weight loss may influence patients’ cancer risk, usually lowering it but sometimes possibly increasing it, new findings suggest.

Eli Lilly's (LLY) recent earnings and GLP-1 trial results shook the biopharma market this week. Courtney Breen, Bernstein ...

Eli Lilly (LLY) reports Q2 earnings on Aug 7, with booming diabetes and weight-loss drug sales driving strong growth.